Sanofi (SNYNF) Operating Income (2009 - 2026)
Sanofi (SNYNF) posted Operating Income of $14.4 billion for Q1 2026, up 7.45% sequentially from $13.4 billion in Q4 2025, and up 15.5% YoY from $12.5 billion in Q1 2025.
Sanofi (SNYNF) Operating Income (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Operating Income data on file, last reported at $14.4 billion in Q1 2026.
- Quarterly Operating Income rose 15.5% year-over-year to $14.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.3 billion (up 33.65% YoY) and the FY2025 annual result came in at $7.4 billion, down 4.71% from the prior year.
- Operating Income climbed to $14.4 billion in Q1 2026 per SNYNF's latest filing, from $13.4 billion in the prior quarter.
- The five-year high for Operating Income was $52.4 billion in Q4 2023, with the low at $12.1 billion in Q1 2024.
- Average Operating Income over 5 years is $18.5 billion, with a median of $13.9 billion recorded in 2025.
- Year-over-year, Operating Income sank 52.39% in 2024 and surged 201.14% in 2025.
- Sanofi's Operating Income stood at $17.8 billion in 2022, then jumped by 193.46% to $52.4 billion in 2023, then slumped by 52.39% to $24.9 billion in 2024, then slumped by 46.26% to $13.4 billion in 2025, then climbed by 7.45% to $14.4 billion in 2026.
- Business Quant data shows SNYNF's Operating Income at $14.4 billion in Q1 2026, $13.4 billion in Q4 2025, and $44.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 9.50 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 6.36 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 3.99 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 4.25 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | 14.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.40 Bn |
| Dec 31, 2025 | 13.40 Bn |
| Sep 30, 2025 | 44.62 Bn |
| Jun 30, 2025 | 13.88 Bn |
| Mar 31, 2025 | 12.47 Bn |
| Dec 31, 2024 | 24.93 Bn |
| Sep 30, 2024 | 14.82 Bn |
| Jun 30, 2024 | 12.35 Bn |
| Mar 31, 2024 | 12.12 Bn |
| Dec 31, 2023 | 52.37 Bn |
| Sep 30, 2023 | 14.54 Bn |
| Jun 30, 2023 | 12.99 Bn |
| Mar 31, 2023 | 13.09 Bn |
| Dec 31, 2022 | 20.62 Bn |
| Sep 30, 2022 | 14.18 Bn |
| Jun 30, 2022 | 13.17 Bn |
| Mar 31, 2022 | 12.59 Bn |
| Dec 31, 2021 | 25.75 Bn |
| Sep 30, 2021 | 13.53 Bn |
| Jun 30, 2021 | 12.17 Bn |